How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

209 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. (PubMed)

Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. Ciclopirox 8% nail lacquer has recently become the first topical antifungal agent to be approved by the US Food and Drug Administration for the treatment of onychomycosis. This article reviews the results of the two pivotal clinical trials of this drug that have been performed in the United States as well as those that have been carried out in other countries. The two US studies were both double (...) -blind, vehicle-controlled, parallel-group, multicenter studies designed to determine the efficacy and safety of ciclopirox nail lacquer in the treatment of mild-to-moderate onychomycosis of the toenails caused by dermatophytes. The combined results show a 34% mycologic cure rate, as compared with 10% for the placebo. Data from the ten studies conducted worldwide show a meta-analytic mean (+/- SE) mycologic cure rate of 52.6% +/- 4.2%. As expected for a topical agent, ciclopirox nail lacquer

2001 Journal of the American Podiatric Medical Association

202. [Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. (PubMed)

[Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. Anti-inflammatory actions of ciclopirox, an antifungal agent, have been described previously. We assessed the effectiveness of ciclopirox in the treatment of viral warts.Twenty-three immunocompetent patients (age 9-61 years) with common warts at the hands, feet and in the face resistant to conventional therapy were treated. Following keratolysis with a salicylic acid-containing patch, an 8% ciclopirox (...) lacquer was applied 1-2 times daily. At the beginning and the end of the treatment lesions were photographed and the time span (minimum 4 weeks) until complete resolution was documented.In 7 patients complete remission, and in 12 patients partial remission was achieved. Only 4 patients did not show any effect under topical ciclopirox treatment (mean duration of therapy 3.2 +/- 2.1 months). The overall response rate was 82.6%. Local side effects like erythema or pruritus were not reported.Our data

2001 Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete

203. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. (PubMed)

Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. Onychomycosis is a relatively common condition affecting toenails more than fingernails. It is caused predominantly by dermatophytes. Onychomycosis can cause pain and discomfort and has the potential to be a source of morbidity.We evaluated the efficacy and safety of ciclopirox nail lacquer solution 8% used to treat onychomycosis of the toe in the United States and in centers worldwide.Two identically (...) designed, double-blind, vehicle controlled, parallel group multicenter studies were performed in the United States to evaluate the use of ciclopirox nail lacquer to treat mild to moderate toe onychomycosis caused by dermatophytes. In the first study, 223 patients were randomized to treatment (ciclopirox group: 112, vehicle group: 111), and in the second study, 237 subjects were randomized (ciclopirox group: 119, vehicle group: 118). Before randomization, patients were to have clinical features

2000 Journal of the American Academy of Dermatology

204. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis (PubMed)

A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis The association between seborrhoeic dermatitis and dandruff and the yeast Malassezia furfur is well recognized. Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective (...) treatment for these scalp conditions. Salicylic acid has keratolytic properties and aids in the removal of scales.To compare the therapeutic efficacy of a shampoo containing 1.5% ciclopirox olamine and 3% salicylic acid (CPO/SA) with Nizoral (2.0% ketoconazole shampoo) in a study involving 154 subjects with dandruff - 70 of whom also had seborrhoeic dermatitis of the scalp. Nizoral is currently a registered treatment for dandruff and seborrhoeic dermatitis.The shampoos were used three times week for 4

2002 Journal of Dermatological Treatment

205. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. (PubMed)

Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. In separate multicentre, randomized, double-blind clinical trials, 1% ciclopirox olamine cream was compared with its cream vehicle and with 1% clotrimazole cream as treatment for tinea corporis and tinea cruris. Patients who demonstrated clinical and mycological findings consistent with the diagnoses of tinea corporis or tinea cruris were included in the study. Clinical (...) and mycological evaluations were made pretreatment, at the end of each of the four weeks of treatment, and weekly for the two weeks immediately following cessation of treatment. In both studies, use of ciclopirox olamine cream resulted in demonstrable improvements after the first week of therapy and in complete clinical and mycological clearing in two thirds of the patients at the end of the treatment period. These results were maintained through the two-week drug-free observation period that followed the end

1986 The Journal of international medical research

206. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. (PubMed)

Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Two randomized, double-blind, parallel-group studies, each conducted at five medical centers, assessed the efficacy and safety of a new antifungal agent, ciclopirox olamine cream 1%, in patients with tinea versicolor. In one study, the antifungal agent was compared with its cream vehicle; in the other, it was compared with another antifungal compound, 1% clotrimazole cream. In both studies, treatments were (...) applied twice daily for 14 days. Results with ciclopirox olamine cream were significantly better (P less than 0.05) than those with the vehicle alone after one and two weeks of therapy and at one and two weeks posttherapy. After two weeks of treatment, 49% of the 73 patients treated with the antifungal cream were clinically and mycologically cured, whereas only 24% of the 72 patients using the vehicle were similarly cured (P less than 0.001). The clinical cure rate with ciclopirox olamine cream also

1985 Clinical therapeutics

207. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. (PubMed)

Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. The efficacy and safety of a new antimycotic agent, ciclopirox olamine, were evaluated in two multicenter, randomized, double-blind trials in patients with clinically and mycologically diagnosed cutaneous candidosis. Patients applied the assigned drug twice daily for 28 days. In the first comparison, significantly better clinical and mycological results were obtained in the 74 patients treated (...) with ciclopirox olamine than in the 70 patients treated with the vehicle only. The highly significant differences between treatment groups persisted through the final visit, two weeks posttreatment. In the second study, after one, two, and three weeks of treatment, significantly better clinical responses were seen in the 48 patients treated with ciclopirox olamine than in the 48 treated with clotrimazole. Mycological responses, however, were similar in the two treatment groups over the four-week treatment

1985 Clinical therapeutics

208. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. (PubMed)

Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. Recently a novel topical nail lacquer, ciclopirox solution 8%, has been approved for the treatment of onychomycosis.This was undertaken to determine the most cost-effective treatment for the treatment of dermatophyte onychomycosis of the toes in the United States in 2000.The nature of the problem was defined. The drug comparators (...) were ciclopirox nail lacquer, terbinafine, itraconazole (pulse), itraconazole (continuous), fluconazole, and griseofulvin. A decision analytic model that reflected the manner in which pedal tinea unguium is managed was produced. Studies that have evaluated the efficacy of the nail lacquer and the oral antifungal agents for this indication were identified. Appropriate studies were used in a meta-analysis to determine the mycologic and clinical response rates when the drug comparators are used

2000 Journal of the American Academy of Dermatology

209. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. (PubMed)

Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. The hydroxypyridone antifungal agent ciclopirox olamine cream 1% has been shown to be as effective in the treatment of inflamed, superficial fungal infections as a formulation in which ciclopirox 1% and hydrocortisone acetate 1% were combined. In a randomized, double-blind, parallel group comparison study, 138 patients with culture-confirmed superficial

1988 Clinical therapeutics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>